Component
Knee symptoms and function assessed by WOMAC
Knee symptoms and function assessed by WOMAC. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"}
- experimental_model
- Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort
- exposure
- Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose
- limitations
- Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict.
- nutrient_topic
- Boron research collection; topical membership is not evidence of a direct dietary effect. · Boron
- organism
- Human
- plain_language
- The combined knee symptom/function score improved at two weeks; the one-week result was uncertain.
- primary_references
- [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
- tissue_or_cell_type
- Pain and WOMAC questionnaire outcomes
Boron: chemistry, nutrient interactions, low-intake studies and mechanistic uncertainties (2026-09-17) · lines 1080–1091
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort · source_derived_draft · unverified_draft
### boron-fructoborate-womac The WOMAC treatment difference was −13.73 at day 14 (p<0.0001); the day-seven difference of −5.3 had p=0.06 and was not conventionally significant. Condition category: normal nutrient_topic: Boron research collection; topical membership is not evidence of a direct dietary effect. plain_language: The combined knee symptom/function score improved at two weeks; the one-week result was uncertain. organism: Human tissue_or_cell_type: Pain and WOMAC questionnaire outcomes experimental_model: Randomized placebo-controlled trial; 60 participants with self-reported knee discomfort limitations: Short symptom trial. The 2021 correction (PMID 33564230, https://pubmed.ncbi.nlm.nih.gov/33564230/) disclosed FutureCeuticals funding/product supply, company employment and patent interests; the journal requested retrospective registration. Day-seven WOMAC p=0.06 was not conventionally significant despite broader wording in the original abstract. These are corrections/qualifications, not a new scientific conflict. exposure: Calcium fructoborate 110 mg twice daily for 14 days; compound mass is not elemental boron dose evidence_span: {"source_cache": "artifacts/boron-research/24940052.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be", "start_char": 0, "end_char": 1393, "text_sha256": "67109609237051de9522fd8d5c1dc3a6d96babf2f8b3931e4564c675f88c80be"} [boron-p24940052] Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. (2014). https://pubmed.ncbi.nlm.nih.gov/24940052/ DOI: 10.2147/cia.s64590
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.